Jaguar Animal Health (NASDAQ:JAGX) Shares Cross Below 50 Day Moving Average – What’s Next?

Jaguar Animal Health, Inc. (NASDAQ:JAGX) passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $9.58 and traded as low as $4.47. Jaguar Animal Health shares last traded at $4.79, with a volume of 1,074,769 shares.

Analyst Ratings Changes

A number of research firms have recently weighed in on JAGX. Wall Street Zen raised Jaguar Animal Health to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

Jaguar Animal Health Trading Up 5.7%

The stock has a market cap of $1.63 million, a PE ratio of -0.00 and a beta of -0.11. The stock has a 50-day moving average price of $9.58 and a two-hundred day moving average price of $60.25. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.69 and a quick ratio of 0.40.

Jaguar Animal Health (NASDAQ:JAGX) last posted its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($782.25) by $766.55. The business had revenue of $1.23 million during the quarter, compared to the consensus estimate of $4.24 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America.

The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S.